Streetbeat News

Earnings

PETQ

PetIQ reported Q4 2023 adjusted EPS of $(0.12), surpassing the $(0.29) estimate, and sales of $219.93M, exceeding the $189.05M estimate. This represents a 20% decrease in losses per share and a 19.47% increase in sales compared to the same period last year.

Portfolio Pulse from Benzinga Newsdesk

February 28, 2024 | 9:36 pm

CSTL

Castle Biosciences (NASDAQ:CSTL) reported Q4 earnings, beating estimates with an EPS of $-0.1 against an expected $-0.54. Revenue increased by $27.78 million from the previous year. The company has a history of surpassing EPS estimates, leading to a share price increase.

Portfolio Pulse from Benzinga Insights

February 28, 2024 | 9:35 pm

CDXS

Codexis (NASDAQ:CDXS) reported Q4 earnings, beating estimated earnings by 17.0% with an EPS of $-0.1 versus an estimate of $-0.12. However, revenue was down $3.81 million from the same period last year. In the previous quarter, Codexis also beat EPS estimates which led to a 7% increase in share price the next day. The company has shown a mixed performance in past quarters with fluctuations in EPS and revenue.

Portfolio Pulse from Benzinga Insights

February 28, 2024 | 9:35 pm

AVIR

Atea Pharmaceuticals (NASDAQ:AVIR) reported Q4 earnings, beating estimates by 6.0% with an EPS of $-0.47. However, revenue remained unchanged from the previous year. Despite beating last quarter's EPS estimates, the share price dropped by 9.0% the following day.

Portfolio Pulse from Benzinga Insights

February 28, 2024 | 9:35 pm

CRNX

Crinetics Pharmaceuticals (NASDAQ:CRNX) reported a Q4 EPS loss of $(0.90), missing the consensus estimate of $(0.86) by 4.65%. This represents a 7.14% increase in losses compared to the same period last year.

Portfolio Pulse from saritha@benzinga.com

February 28, 2024 | 9:35 pm

ZUO

Zuora (NYSE:ZUO) reported Q4 earnings with an EPS of $0.12, beating estimates by 140% and showing a revenue increase of $7.63 million year-over-year. The company has consistently beaten EPS estimates in the past four quarters, with the share price increasing by 9.0% the day after last quarter's earnings announcement. Zuora provided Q4 2024 earnings guidance of $0.04 to $0.05 per share.

Portfolio Pulse from Benzinga Insights

February 28, 2024 | 9:35 pm

DMRC

Digimarc (NASDAQ:DMRC) reported Q4 earnings with an EPS of $-0.28, beating estimates by 12.0% and showing a revenue increase of $2.07 million from the previous year. The company has consistently beaten EPS estimates over the past four quarters, leading to a 2.0% share price increase after last quarter's earnings announcement.

Portfolio Pulse from Benzinga Insights

February 28, 2024 | 9:35 pm

ORN

Orion Gr Hldgs (NYSE:ORN) reported Q4 earnings, beating estimates with an EPS of $0.08, double the expected $0.04. Revenue increased by $5.40 million year-over-year. The company has a history of beating EPS estimates, which previously led to an 8% share price increase the following day.

Portfolio Pulse from Benzinga Insights

February 28, 2024 | 9:35 pm

UMH

UMH Properties reported Q4 2023 earnings of $0.23 per share, surpassing the consensus estimate of $0.22. Sales reached $56.98M, exceeding the $55.79M estimate and marking a 16.90% increase from the previous year.

Portfolio Pulse from Benzinga Newsdesk

February 28, 2024 | 9:35 pm

CRNX

Crinetics Pharmaceuticals (NASDAQ:CRNX) reported Q4 earnings with an EPS of $-0.9, missing estimates by -5.0% and showing a revenue decrease of $709 thousand from the previous year. This follows a pattern of missed EPS estimates in previous quarters, with a notable 4.0% share price drop after last quarter's earnings miss.

Portfolio Pulse from Benzinga Insights

February 28, 2024 | 9:35 pm